Garvan Institute of Medical Research

38 items matching your search terms.

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer: Baker, L. A.; Holliday, H.; Roden, D.; Krisp, C.; Wu, S. Z.; Junankar, S.; Serandour, A. A.; Mohammed, H.; Nair, R.; Sankaranarayanan, G.; Law, A. M. K.; McFarland, A.; Simpson, P. T.; Lakhani, S.; Dodson, E.; Selinger, C.; Anderson, L.; Samimi, G.; Hacker, N. F.; Lim, E.; Ormandy, C. J.; Naylor, M. J.; Simpson, K.; Nikolic, I.; O'Toole, S.; Kaplan, W.; Cowley, M. J.; Carroll, J. S.; Molloy, M.; Swarbrick, A.; BREAST CANCER RES 22 (1) :63, 2021 10.1186/s13058-020-01306-6

Estrogen receptor positive breast cancer patient derived xenograft models in translational research.: Chia, K.; Freelander, A.; Kumar, S.; Parker, A.; Segara, D.; Portman, N.; Lim, E.; Current Opinion in Endocrine and Metabolic Research 15 :31-36, 2020

Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer: de Boer, R.; Hui, R.; Lim, E.; Yeo, B.; Zdenkowski, N.; Asia-Pacific Journal of Clinical Oncology 16 Suppl 5 :3-14, 2020 10.1111/ajco.13461

Stromal cell diversity associated with immune evasion in human triple-negative breast cancer: Wu, S. Z.; Roden, D. L.; Wang, C.; Holliday, H.; Harvey, K.; Cazet, A. S.; Murphy, K. J.; Pereira, B.; Al-Eryani, G.; Bartonicek, N.; Hou, R.; Torpy, J. R.; Junankar, S.; Chan, C. L.; Lam, C. E.; Hui, M. N.; Gluch, L.; Beith, J.; Parker, A.; Robbins, E.; Segara, D.; Mak, C.; Cooper, C.; Warrier, S.; Forrest, A.; Powell, J.; O'Toole, S.; Cox, T. R.; Timpson, P.; Lim, E.; Liu, X. S.; Swarbrick, A.; EMBO JOURNAL 1 (39) :e104063, 2020 10.15252/embj.2019104063

Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender man: Light, M.; McFarlane, T.; Ives, A.; Shah, B.; Lim, E.; Grossmann, M.; Zajac, J. D.; Cheung, A. S.; CLINICAL ENDOCRINOLOGY 93 (3) :355-357, 2020 10.1111/cen.14263

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer: Portman, N.; Milioli, H. H.; Alexandrou, S.; Coulson, R.; Yong, A.; Fernandez, K. J.; Chia, K. M.; Halilovic, E.; Segara, D.; Parker, A.; Haupt, S.; Haupt, Y.; Tilley, W. D.; Swarbrick, A.; Caldon, C. E.; Lim, E.; BREAST CANCER RESEARCH 22 (1) :87, 2020 10.1186/s13058-020-01318-2

Targeting CDK2 in cancer: challenges and opportunities for therapy: Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.; DRUG DISCOVERY TODAY 25 (2) :406-413, 2020 10.1016/j.drudis.2019.12.001

Window of opportunity treatment in breast cancer: Chen, J.; Easwaralingam, N.; Warrier, S.; Ong, A.; Carson, E. K.; Mak, C.; Snook, K.; Middleton, K.; Parker, A.; Palmieri, C.; Spillane, A.; Mann, G. B.; Lim, E.; Segara, D.; ANZ JOURNAL OF SURGERY 90 (1-2) :34-40, 2020 10.1111/ans.15487

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary: Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H. J.; MEDICAL JOURNAL OF AUSTRALIA 211 (5) :224-229, 2019 10.5694/mja2.50280

Estrogen receptor signaling is reprogrammed during breast tumorigenesis: Chi, D.; Singhal, H.; Li, L.; Xiao, T.; Liu, W.; Pun, M.; Jeselsohn, R.; He, H.; Lim, E.; Vadhi, R.; Rao, P.; Long, H.; Garber, J.; Brown, M.; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 116 (23) :11437-11443, 2019 10.1073/pnas.1819155116

The International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology: Field, A. S.; Raymond, W. A.; Rickard, M.; Arnold, L.; Brachtel, E. F.; Chaiwun, B.; Chen, L.; Di Bonito, L.; Kurtycz, D. F. I.; Lee, A. H. S.; Lim, E.; Ljung, B. M.; Michelow, P.; Osamura, R. Y.; Pinamonti, M.; Sauer, T.; Segara, D.; Tse, G.; Vielh, P.; Chong, P. Y.; Schmitt, F.; ACTA CYTOL 63 (4) :257-273, 2019 10.1159/000499509

Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes: Young, A. R.; Duarte, J. D. G.; Coulson, R.; O'Brien, M.; Deb, S.; Lopata, A.; Behren, A.; Mathivanan, S.; Lim, E.; Meeusen, E.; Cancers 11 (5) :682, 2019 10.3390/cancers11050682

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer: Kennedy, S. P.; Han, J. Z. R.; Portman, N.; Nobis, M.; Hastings, J. F.; Murphy, K. J.; Latham, S. L.; Cadell, A. L.; Miladinovic, D.; Marriott, G. R.; O'Donnell, Y. E. I.; Shearer, R. F.; Williams, J. T.; Munoz, A. G.; Cox, T. R.; Watkins, D. N.; Saunders, D. N.; Timpson, P.; Lim, E.; Kolch, W.; Croucher, D. R.; BREAST CANCER RESEARCH 21 (1) :43, 2019 10.1186/s13058-019-1127-y

The proliferative and apoptotic landscape of basal-like breast cancer: Alexandrou, S.; George, S. M.; Ormandy, C. J.; Lim, E.; Oakes, S. R.; Caldon, C. E.; INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20 (3) :667, 2019 10.3390/ijms20030667